ライフサイエンスコーパス: trabeculectomy

1 necessarily represent clinical failure after trabeculectomy.

2 eyes that have undergone previous successful trabeculectomy.

3 th caution, especially in eyes with previous trabeculectomy.

4 rs potentially associated with low IOP after trabeculectomy.

5 likely to have had hypotony after study eye trabeculectomy.

6 receive selective laser trabeculoplasty and trabeculectomy.

7 LO as adjuvant compared to low-dosage MMC in trabeculectomy.

8 nly utilized to enhance the success rates of trabeculectomy.

9 m had failed or were at high risk of failing trabeculectomy.

10 s at the time of their MMC-augmented primary trabeculectomy.

11 as increased the rate of complications after trabeculectomy.

12 on to mitomycin concentration applied during trabeculectomy.

13 al application using surgical sponges during trabeculectomy.

14 , and $29 055 per QALY for tube insertion vs trabeculectomy.

15 on after EX-PRESS implantation compared with trabeculectomy.

16 after treatment with the EX-PRESS device and trabeculectomy.

17 functional improvements may occur following trabeculectomy.

18 to private patients with attending-performed trabeculectomy.

19 eated with EX-PRESS and 61 eyes treated with trabeculectomy.

20 ents with uncontrolled glaucoma after failed trabeculectomy.

21 ent a successful right Mitomycin C-augmented trabeculectomy.

22 g bleb in patients after previous successful trabeculectomy.

23 dary glaucoma, and 37% had previously failed trabeculectomy.

24 ed as the most frequent late complication of trabeculectomy.

25 ive procedures such as tube-shunts or repeat trabeculectomy.

26 d change in visual acuity since the original trabeculectomy.

27 que to repair late-onset leaking blebs after trabeculectomy.

28 r nonpenetrating deep sclerectomy (NPDS) and trabeculectomy.

29 low-up in eyes following previous successful trabeculectomy.

30 e consecutive visits 3 months or later after trabeculectomy.

31 s patients who underwent attending-performed trabeculectomies.

32 85 eyes) or combined phacoemulsification and trabeculectomy (10 eyes) and were randomized to MMC or C

33 The preceding surgeries were trabeculectomy (11 eyes), cataract surgery (10 eyes), an

34 significantly greater than in patients after trabeculectomy (2/61 [3%]; 95% confidence interval, 0.4-

35 te: trabeculectomy 61.8%, tube 44.9%; Black: trabeculectomy 20.8%, tube 35.6%; P = .003) and the perc

36 gistry cohort included 419 eyes: 183 (43.7%) trabeculectomy; 236 (56.3%) tube.

37 5% CI, $1644-$1770) for medical treatment vs trabeculectomy, $3904 (95% CI, $3858-$3953) for medical

38 Trabeculotomy+/-trabeculectomy (6 eyes) had 17% success rate with 14.8 +

39 een treatment groups, including race (White: trabeculectomy 61.8%, tube 44.9%; Black: trabeculectomy

40 laucoma subspecialists performed most of the trabeculectomies (76.7% in 2008, 83.1% in 2016) and GDI

41 ion of preoperative IOP were achieved by 337 trabeculectomies (78%) without IOP-lowering treatment an

42 beculoplasty (18.6% vs 9.6%; P < .0001), and trabeculectomy (8.1 vs 1.8%; P < .0001) and experienced

43 evious incisional glaucoma surgery underwent trabeculectomy (85 eyes) or combined phacoemulsification

44 %) without IOP-lowering treatment and by 367 trabeculectomies (86%) including hypotensive medication.

45 he percentage of follow-up visits completed (trabeculectomy 88.4%, tube 83.8%, P = .004).

46 thetic) has gained popularity for its use in trabeculectomy, a filtering surgery for glaucoma.

47 than in the group of patients who underwent trabeculectomy after 6 months (p = 0.003), 12 months (p

48 either a glaucoma drainage implant (tube) or trabeculectomy after a previous trabeculectomy and/or ca

49 Compared to trabeculectomy after PK, trabeculectomy after DSAEK achieved lower mean IOP at 12

50 Trabeculectomy after failed goniotomy surgery or as a pr

51 Trabeculectomy after phacoemulsification was uncommon; t

52 Compared to trabeculectomy after PK, trabeculectomy after DSAEK achi

53 o-bypass (TMB) implantation or by ab interno trabeculectomy (AIT).

54 ymptoms from those that underwent fellow eye trabeculectomy (all P > .05).

55 ction was lower for patients undergoing both trabeculectomy alone (0.09%-0.03%; P = 0.27) and combine

56 tomy (SCB: 6; C: 3), NPGS (SCB: 3; C: 2) and trabeculectomy alone (SCB: 1; C: 1).

57 his is a promising solution to rescue failed trabeculectomies and can potentially prolong trabeculect

58 EX-PRESS shunt, compared to trabeculectomy and Ahmed valve, seems to be a safer proc

59 =4 reliable VF measurements before and after trabeculectomy and at least 4 years of follow-up before

60 ange was not significantly different between trabeculectomy and control intervals (p=.37).

61 of IOP in the eyes after previous successful trabeculectomy and deterioration of filtering bleb morph

62 The time between trabeculectomy and each outcome was compared between cas

63 eatment with phacoemulsification, ab-interno trabeculectomy and endoscopic cyclophotocoagulation effe

64 The percentage for trabeculectomy and GDIs decreased from 92.3% to 21.2%.

65 d to traditional glaucoma surgeries, such as trabeculectomy and glaucoma drainage device implantation

66 onal incisional glaucoma surgery techniques (trabeculectomy and glaucoma drainage implant [GDI] proce

67 mitomycin C-augmented combined trabeculotomy-trabeculectomy and may be recommended as the initial sur

68 The types of GFS included trabeculectomy and non-penetrating glaucoma surgery (NPG

69 In the group of patients subjected to both trabeculectomy and phacoemulsification, mean IOP was sig

70 ected to promote attachment, 1 eye (2%) with trabeculectomy and progressive synechiae demonstrated la

71 ors for low intraocular pressure (IOP) after trabeculectomy and to describe long-term outcomes in the

72 The continued movement away from trabeculectomy and toward alternative intraocular pressu

73 ng a willingness to pay of $50 000 per QALY, trabeculectomy and tube insertion are cost-effective com

74 Trabeculectomy and tube shunt surgery had similar impact

75 vertime, and the five-year failure rates for trabeculectomy and tube shunts are 25-45%.

76 f filtering-associated endophthalmitis after trabeculectomy and tube-shunt implantation.

77 , or pigmentary glaucoma, who failed a first trabeculectomy and who were >/=40 years of age at the ti

78 of 1959 eyes of 1423 patients who underwent trabeculectomy and who were followed for >/=1 year were

79 nt (tube) or trabeculectomy after a previous trabeculectomy and/or cataract extraction; extracted cli

80 nd the incidence of complications related to trabeculectomy and/or corneal graft surgery.

81 (DMEK) in eyes that had previously undergone trabeculectomy and/or drainage device implantation.

82 o Cucamonga, CA]), 61 patients had undergone trabeculectomy, and 87 patients were medically treated.

83 n, trabecular micro-bypass stent, ab interno trabeculectomy, and canaloplasty may be performed in con

84 nfants underwent combined trabeculotomy with trabeculectomy, and goniotomy was possible in 1 infant.

85 ery was found in similar proportions of GDD, trabeculectomy, and medically treated cases (3/47 [6%],

86 imilar proportion of medically treated, post-trabeculectomy, and post-GDD cases (4/87 [5%], 4/61 [7%]

87 The utility gained after medical treatment, trabeculectomy, and tube insertion was 3.10, 3.30, and 3

88 The mean costs for medical treatment, trabeculectomy, and tube insertion were $6172, $7872 and

89 st-effectiveness ratio of medical treatment, trabeculectomy, and tube insertion.

90 s would be viscocanalostomy, thereby keeping trabeculectomy as an alternative.

91 Proportion of failed trabeculectomies at 24 months, defined as the need for r

92 Review of 881 eyes that underwent trabeculectomy at an academic glaucoma service between J

93 l study was performed of patients undergoing trabeculectomy at the Stein Eye Institute.

94 tients) underwent resident-performed primary trabeculectomy at the VAH with mean follow-up duration o

95 omy (Group I) or combined trabeculotomy with trabeculectomy augmented with mitomycin C (Group II).

96 Clinical studies comparing trabeculectomy augmented with Ologen implant (OLO) versu

97 sicians ("attendings") who underwent primary trabeculectomy between 2003 and 2012 with >/=6 months of

98 st 12 years of age coded as having undergone trabeculectomy between May 2000 and October 2008 by 1 of

99 my on the intraocular pressure (IOP) and the trabeculectomy bleb integrity, in a small series of eyes

100 aucoma procedures appear less effective than trabeculectomy, but they are associated with a lower ris

101 Consecutive trabeculectomy cases with open-angle glaucoma and no pre

102 urgery was hypertropia (10/11 GDD cases, 2/2 trabeculectomy cases).

103 hty-five patients were included in the final trabeculectomy cohort after accounting for declining tre

104 and other bleb-related complications in the trabeculectomy cohort of the Collaborative Initial Glauc

105 most commonly with goniotomy, trabeculotomy, trabeculectomy, combined trabeculotomy and trabeculectom

106 the first postoperative day but higher after trabeculectomy compared with EX-PRESS implant on day 7 (

107 identified using glaucoma surgical codes for trabeculectomy, complicated trabeculectomy, glaucoma dra

108 ntify studies representative of the reported trabeculectomy complication rate.

109 a (18.5%), adverse drug effects (14.5%), and trabeculectomy complications (8.7%).

110 Association between the rate of trabeculectomy complications and mitomycin dose used was

111 No difference was observed between NPDS and trabeculectomy concerning these structural modifications

112 In the subjects who underwent trabeculectomy, corneal endothelial cell density (ECD) s

113 rabeculectomy, or combined trabeculotomy and trabeculectomy (CTT) as primary surgery from 1997 throug

114 s underwent goniotomy or trabeculotomy, with trabeculectomy depending on corneal clarity.

115 Successful trabeculectomies, determined by Kaplan-Meier analysis, i

116 Eligible patients who refused fellow eye trabeculectomy did not differ significantly in visual fu

117 ed phacoemulsification technique, ab-interno trabeculectomy dual blade and endoscopic cyclophotocoagu

118 s of age) underwent an MMC-augmented primary trabeculectomy during the period from April 1996 to Janu

119 bility of bleb-related infections long after trabeculectomy, especially in the presence of identified

120 efractive surprise in cataract surgery after trabeculectomy, especially IOP change and axial length,

121 efractive outcome was -0.36 (more myopic) in trabeculectomy eyes compared with +0.23 (more hyperopic)

122 Mean intraocular pressure (IOP) increased in trabeculectomy eyes from 8.7 +/- 4.2 mm Hg to 10.7 +/- 4

123 underwent needling, respectively, and 50% of trabeculectomy eyes underwent laser suture lysis.

124 57 post-trabeculectomy eyes were included.

125 med to identify risk factors associated with trabeculectomy failure at 8 years.

126 The primary outcome was trabeculectomy failure defined as intraocular pressure (

127 75 were offered trabeculectomy: five agreed but only one underwent surge

128 nitial treatment with topical medications to trabeculectomy for 607 participants with newly diagnosed

129 and complications of fornix- vs limbal-based trabeculectomy for glaucoma were compared in adult glauc

130 after surgery, whereas the success rates of trabeculectomy for patients who were not treated with TN

131 The success rate of trabeculectomy for patients who were treated with TNF in

132 ainage devices are preferred to conventional trabeculectomy for the treatment of secondary glaucoma.

133 f Olmsted County, Minnesota, who underwent a trabeculectomy from January 1, 1985, through December 31

134 rgical codes for trabeculectomy, complicated trabeculectomy, glaucoma drainage device, and cycloablat

135 Glaucoma surgical procedures, including trabeculectomy, glaucoma drainage implants (GDIs), and s

136 /-1.4 in the tube group and 1.2+/-1.5 in the trabeculectomy group (P < 0.001).

137 the tube group and 39 patients (37%) in the trabeculectomy group (P = .012).

138 rate was 9% in the tube group and 29% in the trabeculectomy group (P = .025).

139 the tube group and 12.6 +/- 5.9 mm Hg in the trabeculectomy group (P = .12).

140 tube group, and 0%, 9%, 20%, and 47% in the trabeculectomy group (P = .28).

141 ons was 22% in the tube group and 18% in the trabeculectomy group (P = .29).

142 he tube group and 9 phakic eyes (43%) in the trabeculectomy group (P = .43).

143 ient in the tube group and 5 patients in the trabeculectomy group (P = .63).

144 1.3 in the tube group and 1.4 +/- 1.4 in the trabeculectomy group (P = .71).

145 e tube group and 30.5 +/- 20.4 months in the trabeculectomy group (P = .76).

146 the tube group and 14.4 +/- 6.6 mm Hg in the trabeculectomy group (P = .84).

147 he Baerveldt group and 34+/-20 months in the trabeculectomy group (P = 0.053).

148 in the tube group and 9 patients (8%) in the trabeculectomy group (P = 0.11).

149 -up was 33% in the tube group and 28% in the trabeculectomy group (P = 0.17; hazard ratio, 1.39; 95%

150 as 87% in the Baerveldt group and 76% in the trabeculectomy group (P = 0.23).

151 Baerveldt group and 20 patients (29%) in the trabeculectomy group (P = 0.27).

152 r in the tube group and -0.38 dB/year in the trabeculectomy group (P = 0.34).

153 ube shunt group and -13.18 +/- 8.2 dB in the trabeculectomy group (P = 0.99).

154 in the tube group and 12.1+/-4.8 mmHg in the trabeculectomy group at 3 years (P = 0.008), and the num

155 nts in the tube group and 18 patients in the trabeculectomy group in the TVT Study, and the 5-year cu

156 .1 mmHg (61.3% reduction) at month 24 in the trabeculectomy group.

157 tube group and -0.56 to -0.20 dB/year in the trabeculectomy group.

158 Both the EX-PRESS and the trabeculectomy groups were treated intraoperatively with

159 ess rate was 83% and 79% in the EX-PRESS and trabeculectomy groups, respectively (P = 0.563).

160 g and 14.6 +/- 7.1 mm Hg in the EX-PRESS and trabeculectomy groups, respectively (P = 0.927).

161 erning these parameters between the NPDS and trabeculectomy groups.

162 Trabeculectomy, however, is cost-effective at a substant

163 Trabeculectomies in eyes with scarring ranged from 9054

164 Trabeculectomies in eyes without previous scarring decre

165 erformed nine trabectome-mediated ab interno trabeculectomies in pig eyes (n = 63).

166 mparable to primary AGV implantation, and to trabeculectomy in eyes with a previously implanted glauc

167 reasonable IOP targets after a first failed trabeculectomy in open-angle glaucoma patients.

168 (thermal sclerostomy) in the 1950s and then trabeculectomy in the 1970s.

169 plications in the 300 patients randomized to trabeculectomy in the Collaborative Initial Glaucoma Tre

170 ared between groups that received or refused trabeculectomy in their fellow eye.

171 tering surgery were included (12 NDPS and 11 trabeculectomies) in this prospective observational stud

172 m parameters showed significant changes with trabeculectomy: increased MRW (+6.04mum, p=.001), increa

173 Performing cataract surgery after trabeculectomy increases the odds of filtration failure

174 ulectomy or combined phacoemulsification and trabeculectomy is associated with similar complete succe

175 Trabeculectomy is the surgical standard of care for pati

176 ith combined phacoemulsification, ab-interno trabeculectomy-Kahook Dual Blade and Endocyclophotocoagu

177 Although trabeculectomy may impede time to recovery from MG, oral

178 In 334 patients, 460 eyes underwent trabeculectomy (mean [SD; range] follow-up, 7.7 [5.7; 0-

179 The potential efficacy of trabeculectomy must be weighed against the long-term ris

180 = 9), glaucoma drainage device (n = 6), and trabeculectomy (n = 1).

181 t-penetrating keratoplasty (n = 2), and post-trabeculectomy (n = 2).

182 tion with IOL implant at least 3 months post-trabeculectomy (n = 77) with eyes with either medically

183 survival rates of goniotomy, trabeculotomy+/-trabeculectomy (no antifibrotics), cycloablation, trabec

184 was negatively correlated with low IOP after trabeculectomy (odds ratio [OR], 0.33; 95% confidence in

185 2 years (95% CI, 0.3-9.9 years), whereas the trabeculectomies of patients who were not treated with T

186 The trabeculectomies of patients who were treated with TNF i

187 ling technique, despite an average time from trabeculectomy of over 4 years.

188 cipants who were randomized to and underwent trabeculectomy on their study eye and had a fellow eye t

189 who were randomized to and underwent initial trabeculectomy on their study eye, and whose fellow eye

190 Patients with uncontrolled IOP requiring trabeculectomy or aqueous drainage device were enrolled.

191 Use of the CM implant at the time of trabeculectomy or combined phacoemulsification and trabe

192 essure (IOP)-lowering efficacy and safety of trabeculectomy or combined phacoemulsification and trabe

193 ative endophthalmitis in patients undergoing trabeculectomy or combined trabeculectomy plus cataract

194 Patients with previous trabeculectomy or glaucoma drainage device (GDD) implant

195 llocated to receive either primary augmented trabeculectomy or primary medical management.

196 found between rate of endophthalmitis after trabeculectomy or tube-shunt implantation (P = 0.761, lo

197 was used to identify all eyes that underwent trabeculectomy or tube-shunt implantation during the stu

198 n was correlated with high vs. low IOP after trabeculectomy (OR, 5.32; 95% CI, 1.53-18.52).

199 h a vent fashioned from the wall of the eye (trabeculectomy) or a glaucoma drainage implant (GDI), bu

200 ildren with PCG who underwent trabeculotomy, trabeculectomy, or combined trabeculotomy and trabeculec

201 ith ischemic nonfunctioning blebs and patent trabeculectomy ostia.

202 This survey shows that good trabeculectomy outcomes with low rates of surgical compl

203 PRESS implant (P = 0.285) and 3 months after trabeculectomy (P = 0.255).

204 The mean number of trabeculectomies per eye was significantly higher in car

205 Of 3659 total trabeculectomies performed by 5 surgeons between 1990 an

206 Glaucoma patients at a VAH with primary trabeculectomy performed by residents under attending su

207 owever, the visual outcomes of patients with trabeculectomy performed by residents were worse in the

208 y alone (0.09%-0.03%; P = 0.27) and combined trabeculectomy plus cataract extraction (0.08%-0.03%; P

209 tients undergoing trabeculectomy or combined trabeculectomy plus cataract extraction.

210 y augmented with Ologen implant (OLO) versus trabeculectomy plus mitomycin-C (MMC) show contradictory

211 e the methodology of the Primary Tube Versus Trabeculectomy (PTVT) Study.

212 The onset of bleb leak following trabeculectomy ranged from 7 months to 16.3 years.

213 The rate of trabeculectomy-related complications does not appear to

214 Trabeculectomy remains the most efficient method of lowe

215 Low IOP after trabeculectomy, reoperation, vision loss, and surgical f

216 Participants who underwent trabeculectomy reported a higher frequency of any Local

217 Trabeculectomy resulted in anatomical changes to the ONH

218 interval between the first and the same-site trabeculectomy revision of <3 years, worse baseline visu

219 significant medication reduction, same-site trabeculectomy revision with MMC should be considered as

220 >/=40 years of age at the time of same-site trabeculectomy revision, were included.

221 Trabeculectomy seems to be the most effective surgical p

222 The intervals containing trabeculectomy showed a significant decrease in intraocu

223 During 2009, 439 trabeculectomy sites of 347 patients were quantitatively

224 The results show that trabeculectomy slows the rate of perimetric decay and pr

225 at an average of 4.3 years from the time of trabeculectomy (standard deviation [SD], 6.5 years) and

226 the Glaucoma Laser Trial and the Tube versus Trabeculectomy Studies were used to assign probabilities

227 Findings of the Tube Versus Trabeculectomy study resulted in an expanded use of tube

228 There is an increasing need to prolong trabeculectomy success rates with minimally invasive pro

229 trabeculectomies and can potentially prolong trabeculectomy success rates.

230 In experimental trabeculectomy surgeries with mitomycin C used as an adj

231 1 patients (80 procedures) who had undergone trabeculectomy surgery after failed medical management a

232 ncontrolled glaucoma underwent microstent or trabeculectomy surgery from January 1, 2011 through July

233 traocular pressure (IOP) predicts outcome of trabeculectomy surgery in patients with primary open ang

234 re-operative IOP does not predict success of trabeculectomy surgery in POAG patients during the first

235 Trabeculectomy surgery prior to MG was associated with p

236 This is particularly true when performing trabeculectomy surgery to enhance ocular fluid outflow a

237 nd secondary glaucoma diagnoses who received trabeculectomy surgery with MMC in an academic medical c

238 Similar efficacy of trabeculectomy surgery with respect to bleb failure or I

239 iveness between fornix-based vs limbal-based trabeculectomy surgery, although with a high level of un

240 The primary outcome was success of trabeculectomy surgery, with failure defined as intraocu

241 f mitomycin C (MMC) to prevent scarring with trabeculectomy surgery.

242 nd its ability to maintain visibility during trabeculectomy surgery.

243 rnix- and limbal-based conjunctival flaps in trabeculectomy surgery.

244 surgery in thirty-eight patients undergoing trabeculectomy (surgical group), using laser scanning co

245 ly compared nonpenetrating surgery (NPS) and trabeculectomy (TE).

246 A contemporary pediatric trabeculectomy technique augmented with MMC is an effect

247 postoperative complications was higher after trabeculectomy than after EX-PRESS implantation (P = 0.0

248 wer rate of cataract surgery performed after trabeculectomy than those in the attending group.

249 systemic TNF inhibitors at the time of their trabeculectomy to control their uveitis, arthritis, or b

250 arate 6-month intervals that did not contain trabeculectomy to serve as control.

251 Patients who underwent trabeculectomy (Trab) with mitomycin-C (74 eyes of 64 pa

252 The Tube vs Trabeculectomy Trial (TVT) found that the 350-mm2 Baerve

253 , trabeculectomy, combined trabeculotomy and trabeculectomy, tube shunt surgery, cyclodestruction, an

254 ty-of-life (QoL) outcomes in the Tube Versus Trabeculectomy (TVT) Study.

255 plopia was more commonly seen after GDD than trabeculectomy, typically a noncomitant restrictive hype

256 Trabeculectomy use continued its long-term downward tren

257 t-effectiveness ratio was $8289 per QALY for trabeculectomy vs medical treatment, $13 896 per QALY fo

258 sertion, and $2203 (95% CI, $2121-$2261) for trabeculectomy vs tube insertion.

259 HR of failure of the microstent relative to trabeculectomy was 1.2 (95% confidence interval [CI], 0.

260 The mean (SD) time of LGP after trabeculectomy was 35.7 (32.3) months, and the mean (SD)

261 Prior trabeculectomy was associated with a higher rate of visi

262 roup of VAH patients with resident-performed trabeculectomy was case-matched to private patients with

263 (control group), in which only a successful trabeculectomy was conducted.

264 The surgical success of the trabeculectomy was expressed as IOP < 17 mmHg.

265 or optic nerve head changes in whom primary trabeculectomy was indicated.

266 el (Group 1), whereas combined trabeculotomy-trabeculectomy was the first-line procedure for PCG in c

267 maximal topical medication and scheduled for trabeculectomy were included in this study at a tertiary

268 t had failed or were at high risk of failing trabeculectomy were randomized to receive an Ahmed impla

269 Control patients without low IOP after trabeculectomy were randomly selected at a 1:2 case-to-c

270 s (study group) in which, after a successful trabeculectomy with 5-Fluorouracil, phacoemulsification

271 Trabeculectomy with anti-fibrotics (14 eyes) showed 57%

272 Trabeculectomy with anti-fibrotics and Baerveldt glaucom

273 culectomy (no antifibrotics), cycloablation, trabeculectomy with anti-fibrotics, and glaucoma drainag

274 In order to lower IOP, trabeculectomy with mitomycin C (0.2 mg/cc) was performe

275 nt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (0.4 mg/ml for 2 minutes

276 rveldt glaucoma implant) and 105 patients to trabeculectomy with mitomycin C (0.4 mg/mL for 4 minutes

277 Trabeculectomy with mitomycin C (8 eyes) and trabeculoto

278 nt surgery (350-mm(2) Baerveldt implant) and trabeculectomy with mitomycin C (MMC) (0.4 mg/ml for 4 m

279 ithin an institutional setting who underwent trabeculectomy with mitomycin C (MMC) for uncontrolled e

280 Trabeculectomy with mitomycin C (MMC) is a major treatme

281 nt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 mi

282 eoperation for glaucoma was higher following trabeculectomy with mitomycin C than tube shunt surgery

283 o overfiltration following glaucoma surgery (trabeculectomy with mitomycin C) were included in this i

284 hat the 350-mm2 Baerveldt implant (tube) and trabeculectomy with mitomycin may be similarly effective

285 m clinical data on the cost-effectiveness of trabeculectomy with mitomycin vs tube insertion.

286 ulectomy or combined phacoemulsification and trabeculectomy with mitomycin-C (MMC) vs. Collagen Matri

287 Trabeculectomy with MMC achieved lower IOP with use of f

288 cations were observed in patients undergoing trabeculectomy with MMC and in those undergoing Baerveld

289 orty glaucoma patients (40 eyes) assigned to trabeculectomy with MMC or Ologen.

290 tandalone ab interno microstent with MMC and trabeculectomy with MMC.

291 nt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with MMC.

292 s was seen after tube shunt implantation and trabeculectomy with MMC.

293 t implantation with mitomycin C (MMC) versus trabeculectomy with MMC.

294 y, -0.42; 95% CI, -0.85 to 0.01; P = 0.053), trabeculectomy with previous surgery (elasticity, -0.28;

295 Patients undergoing trabeculectomy (with or without cataract surgery) or tub

296 eyes of 293 patients (185 microstent and 169 trabeculectomy) with no prior incisional surgery.

297 Trabeculectomy within 6 to 24 months after phacoemulsifi

298 00 eyes of 100 patients previously undergone trabeculectomy without antimetabolites, divided into two

299 nce interval [CI], -1.31 to 0.77; P = 0.61), trabeculectomy without previous surgery (elasticity, -0.

300 uce intraocular pressure (IOP) comparable to trabeculectomy without the risk of serious bleb-related